AMSilk

Overview
Activities
News
Bio-based Materials?
Product stageSegments
Go-to-Market
?
Bio-based textile materials, Bio-based industrial materials
?

AMSilk is a Germany-based company that produces bio-based materials made from spider silk-based proteins. The company has developed a patented biotechnological process to reprogram microorganisms, enabling them to produce silk proteins that can be converted into usable forms such as Silkbeads (microparticles), Silkgel (hydrogel), Biosteel fibers, and coatings. AMSilk's materials have varied application potential across textiles, homecare, biomedical, and automotive sectors. AMSilk claims the high-performance qualities of these silk proteins also make them suitable for developing premium fabrics, technical yarns for automotive interiors, and biofilms and coatings for dishwashing and laundry care products.

AMSilk claims its silk protein-based materials are wholly biodegradable, biocompatible, and do not contain any substances of animal origin or fossil-based raw materials. Based on renewable plant-based feedstock, they are claimed to come with a CO2 greenhouse gas emission reduction of up to 90% and more than 90% less land and water use compared to other protein fibers.

In April 2019, Switzerland-based global cosmetics and fragrance company Givaudan announced plans to acquire the company’s cosmetics business in order to secure the technology behind AMSilk’s high-performance, bio-sourced polypeptides.

In June 2024, AMSilk showcased its biofabricated yarns, which are part of the Biosteel fiber range at the Pitti Filati trade show in Florence, Italy, seeking to connect with leading luxury textile brands and explore commercial collaborations. AMSilk claims that it is the only company to successfully produce filament yarn out of spider silk.


Key customers and partnerships

In January 2022, the company partnered with Mercedes-Benz to provide silk fiber-based door pulls created using Biosteel Fiber for the VISION EQXX concept car. In January 2024, AMSilk announced a partnership with 21st.BIO to accelerate the upscaling of its silk protein production.


Funding and financials

In April 2023, the company raised UR 25 million (~USD 27.3 million) in an extended Series C funding round to support an upscaling of the company’s industrialization and commercialization at the global level.


HQ location:
Am Klopferspitz 19 im IZB Planegg DEU
Founded year:
2008
Employees:
51-100
IPO status:
Private
Total funding:
USD 69.7 mn
Last Funding:
USD 27.4 mn (Series C; Apr 2023)
Last valuation:
-
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.